Friday, 16 October 2026European Markets

AUREA Stock Was Up By 11.51% Before The Weekend

Loading stream...

(vianews) - the market ended the session with aurea (aure.pa) jumping 11.51% to €5.62 on friday while cac 40 slid 1.51% to €7,500.26.

aurea's last close was €5.04, 22.7% under its 52-week high of €6.52.

about aurea

aurea sa engages in the recycling of black motor oil in france. the company is also involved in the manufacturing of remold tires from used tires and recycling rigid pvc. it recycles plastics and packaging products; refines and recycles aluminum; recycles copper and produces copper alloys; and treats and recycles zinc, lead, and cadmium. in addition, the comany engages in the treatment and decontamination of mercury waste. the company was formerly known as auer and changed its name to aurea sa in 1988. aurea sa is based in paris, france.

earnings per share

as for profitability, aurea has a trailing twelve months eps of €0.49.

pe ratio

aurea has a trailing twelve months price to earnings ratio of 11.47. meaning, the purchaser of the share is investing €11.47 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.57%.

yearly top and bottom value

aurea's stock is valued at €5.62 at 22:30 est, way under its 52-week high of €6.52 and way above its 52-week low of €4.30.

moving average

aurea's worth is under its 50-day moving average of €5.65 and above its 200-day moving average of €5.22.

more news about aurea (aure.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com